Skip to main content
Premium Trial:

Request an Annual Quote

Revvity/Honeycomb Biotechnologies Hive CLX Single-Cell RNAseq Solution, BeeNetPlus, Hive CLX Service

Revvity and Honeycomb Biotechnologies have commercially launched the Hive CLX Single-Cell RNAseq solution for sample storage and single-cell profiling, BeeNetPlus analysis workflow, and Hive CLX service for shipping cells to Honeycomb for processing, sequencing, and analysis. Revvity said the Hive CLX Single-Cell RNAseq solution is an upgrade of the portable platform launched by the companies in 2021. It provides higher-density single-cell capture and integrated sample storage in an instrument-free workflow that can be implemented into studies of rare and fragile cell types or of the immune system, among other applications. The BeeNetPlus cloud-based analysis workflow aids interpretation of Hive CLX results by providing reports on sequencing quality, cell type annotation, differential expression, marker gene plots, and cell, gene, and transcripts recovery. The Hive CLX service, available in the US, provides sample-to-result concierge services for single-cell research.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.